Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Mol Hum Reprod ; 11(6): 441-50, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15879465

ABSTRACT

Many studies have implicated numerous hormones, growth factors, cytokines and other signal transduction molecules in the pathogenesis of uterine leiomyoma. Estrogen and estrogen-related genes are thought to play a key role in the growth of uterine leiomyomas, but the molecular mechanisms are unclear. In an attempt to investigate various pathways that might be involved in estrogen-regulated uterine leiomyoma growth as well as to identify any novel effector genes, microarray studies comparing estrogen-treated uterine leiomyoma cells (UtLM) and normal myometrial cells to untreated cells were performed. Several genes were differentially expressed in estrogen treated UtLM cells, including insulin-like growth factor-I (IGF-I) and others potentially involved in the IGF-I signalling pathway, specifically genes for A-myb, a transcription factor which promotes cell cycle progression and for MKP-1, a dual specificity phosphatase that dephosphorylates mitogen-activated protein kinase. IGF-I and A-myb were up-regulated in estrogen-treated cells while MKP-1 was down-regulated. Two other cell cycle promoting genes, c-fos and myc, were also down-regulated in estrogen treated UtLM cells. These genes are typically up-regulated in response to estrogen in some cells, notably breast epithelial cells, yet consistently have lower expression levels in uterine leiomyoma tissue when compared to autologous myometrium. Our results demonstrate some novel genes that may play a role in the growth of uterine leiomyoma, strengthen the case for involvement of the IGF-I pathway in the response of UtLM to estrogen and corroborate evidence that uterine smooth muscle cells respond to estrogen with a different gene expression pattern than that seen in epithelial cells.


Subject(s)
Estrogens/pharmacology , Insulin-Like Growth Factor I/genetics , Leiomyoma/genetics , MAP Kinase Signaling System/genetics , Proto-Oncogene Proteins/genetics , Trans-Activators/genetics , Uterine Neoplasms/genetics , Cell Cycle Proteins/genetics , Dual Specificity Phosphatase 1 , Estrogens/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Immediate-Early Proteins/genetics , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/metabolism , Leiomyoma/immunology , Leiomyoma/metabolism , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , Oligonucleotide Array Sequence Analysis , Phosphoprotein Phosphatases/genetics , Protein Phosphatase 1 , Protein Tyrosine Phosphatases/genetics , Proto-Oncogene Proteins/analysis , Proto-Oncogene Proteins/metabolism , Trans-Activators/analysis , Trans-Activators/metabolism , Tumor Cells, Cultured , Up-Regulation , Uterine Neoplasms/immunology , Uterine Neoplasms/metabolism , Uterus/cytology
2.
Int J Radiat Oncol Biol Phys ; 28(5): 1099-106, 1994 Mar 30.
Article in English | MEDLINE | ID: mdl-8175394

ABSTRACT

PURPOSE: Normal tissue tolerance of boron neutron capture irradiation using borocaptate sodium (NA2B12H11SH) in an epithermal neutron beam was studied. METHODS AND MATERIALS: Large retriever-type dogs were used and the irradiations were performed by single dose, 5 x 10 dorsal portal. Fourteen dogs were irradiated with the epithermal neutron beam alone and 35 dogs were irradiated following intravenous administration of borocaptate sodium. RESULTS: Total body irradiation effect could be seen from the decreased leukocytes and platelets following irradiation. Most values returned to normal within 40 days postirradiation. Severe dermal necrosis occurred in animals given 15 Gy epithermal neutrons alone and in animals irradiated to a total peak physical dose greater than 64 Gy in animals following borocaptate sodium infusion. Lethal brain necrosis was seen in animals receiving between 27 and 39 Gy. Lethal brain necrosis occurred at 22-36 weeks postirradiation. A total peak physical dose of approximately 27 Gy and blood-boron concentrations of 25-50 ppm resulted in abnormal magnetic resonance imaging results in 6 months postexamination. Seven of eight of these animals remained normal and the lesions were not detected at the 12-month postirradiation examination. CONCLUSION: The bimodal therapy presents a complex challenge in attempting to achieve dose response assays. The resultant total radiation dose is a composite of low and high LET components. The short track length of the boron fission fragments and the geometric effect of the vessels causes much of the intravascular dose to miss the presumed critical target of the endothelial cells. The results indicate a large dose-sparing effect from the boron capture reactions within the blood.


Subject(s)
Boron Neutron Capture Therapy , Radiation Tolerance , Animals , Borohydrides/therapeutic use , Brain/radiation effects , Dogs , Dose-Response Relationship, Radiation , Skin/radiation effects , Sulfhydryl Compounds/therapeutic use
3.
Prim Care ; 12(1): 101-15, 1985 Mar.
Article in English | MEDLINE | ID: mdl-2859624

ABSTRACT

The treatment of hypertension must be based on pathophysiologic grounds. The drugs that have been used in the classic stepped-care approach are still useful, but the rationale for their usage should not be based on the presumption that all hypertension is mediated by salt and water. Thus, the adolescent obtains greater benefits from a beta-adrenergic blocking drug or a centrally acting antihypertensive. The individual with heart failure may benefit more from a converting enzyme inhibitor than a vasodilator. In cerebrovascular disease with hypertension, dosage must be reduced owing to the enhanced sensitivity of response. New drugs are discussed, and their place in the armamentarium is evaluated.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Adolescent , Adrenergic beta-Antagonists/therapeutic use , Adult , Aged , Blood Pressure/drug effects , Body Weight/drug effects , Calcium Channel Blockers/therapeutic use , Child , Combined Modality Therapy , Coronary Disease/drug therapy , Diet, Sodium-Restricted , Diuretics/therapeutic use , Heart Failure/drug therapy , Hemodynamics/drug effects , Humans , Hypertension, Renal/drug therapy , Middle Aged , Physical Exertion , Vasodilator Agents/therapeutic use
4.
J Dial ; 3(2-3): 207-18, 1979.
Article in English | MEDLINE | ID: mdl-389974

ABSTRACT

The in vitro plasma protein binding was determined in nine maintenance hemodialysis patients who later underwent renal transplantation. The organic acid fluorescein (10 micrograms/ml) or the organic base quinidine (5 micrograms/ml) was added to the pre and post transplant serum of these patients. Drug concentrations were measured spectrophotofluorometrically after equilibrium dialysis. The results were compared with the plasma protein binding of eight normal volunteers. The patients on maintenance hemodialysis had lower plasma protein binding of fluorescein than normals (78 +/- 5% vs 89 +/- 4, p less than 0.001). Plasma protein binding improved significantly after renal transplantation (85 +/- 3, p less than 0.01) but was still lower than in normals (p 0.05). Plasma protein binding of quinidine was not significantly different than in normal volunteers (77 +/- 8%) either prior to (72 +/- 10%) or after (73 +/- 12%) kidney transplantation. Plasma protein binding of quinidine remains unaffected by renal transplantation. However, the abnormal plasma protein binding or organic acids in chronic renal failure may be significantly improved by renal transplantation.


Subject(s)
Blood Proteins/metabolism , Kidney Transplantation , Adult , Creatinine/blood , Fatty Acids, Nonesterified/blood , Female , Fluoresceins/blood , Humans , Male , Middle Aged , Protein Binding , Quinidine/blood , Renal Dialysis , Serum Albumin , Transplantation, Homologous
5.
J Clin Pharmacol ; 18(8-9): 414-24, 1978.
Article in English | MEDLINE | ID: mdl-690252

ABSTRACT

A phase I dose-response study of 2-aminomethyl-4-(1,1-dimethylethyl)-6-iodophenol HCl (MK-447) was performed with the following oral doses: 6.25, 12.5, 25, 50, and 100 mg. Each volunteer served as his own control. The study was carried out in double-blind fashion on a 5-Gm Na and K diet with a minimum 2000 ml fluid intake. Urine was fractionated and analyzed for sodium, chloride, potassium, calcium, uric acid, and volume. Comparisons (MK-447 minus control values) of the 24-hour total sodium, calcium, potassium, and volume excretion rates at 6.25, 25 and 100 mg MK-447 were as follows: sodium, 195, 345, and 528 muEq/min; chloride, 191, 365, and 756 muEq/min; potassium, 77, -3, and 65 muEq/min; and volumes, 1, 3.4 and 11.7 ml/min. MK-447 did not alter calcium excretion. Uric acid excretion was observed to decrease as the dose of MK-447 was increased, however, the serum uric acid level always remained within normal limits. MK-447 did not alter the physiologic parameters but did produce symptoms of volume contraction at 100 mg. Because no further dose increase was attempted, a plateau in the dose-response curve was not reached. Comparison of 100 mg MK-447 with 80 mg oral furosemide revealed similar potency and a somewhat longer duration of action for MK-447.


Subject(s)
Diuretics , Phenols/pharmacology , Butylated Hydroxytoluene/analogs & derivatives , Chlorides/urine , Furosemide/pharmacology , Humans , Male , Natriuresis/drug effects , Potassium/urine , Time Factors , Uric Acid/urine
6.
Clin Pharmacol Ther ; 23(5): 606-15, 1978 May.
Article in English | MEDLINE | ID: mdl-639436

ABSTRACT

A single-dose kinetic study of oral timolol, 20 mg, was undertaken in 3 groups of volunteers with varying degrees of renal function--(1) 10 normal subjects (N); (2) 9 patients with moderate chronic renal insufficiency (MCRI; C cr, 20 to 50 ml/min); (3) 4 patients with end-stage renal disease (ESRD)--to assess the need for dosage modification as renal function diminishes. There were borderline statistical differences in absorption between groups. The mean peak concentration (C max) was 84.3 +/- 44.8 ng/ml at 0.8 +/- 0.4 hr for N and 87.1 +/- 22.8 ng/ml at 1.7 +/- 1.2 hr (p, NS) for MCRI. N and MCRI mean half-lives (5.2 +/- 2.6 hr and 4.0 +/- 1.2 hr) were not statistically different. Salivary levels correlated with plasma levels in 3 N and 1 MCRI patient. Group differences in blood pressure and pulse response to timolol seems to reflect differences present at baseline with percent change from baseline identical for the two groups except at 12 to 24 hr. Administration of timolol on an interdialysis day revealed similar kinetic and physiologic response in the normal and the MCRI group. During dialysis, timolol, 20 mg, induced significant hypotension and bradycardia.


Subject(s)
Kidney Diseases/metabolism , Propanolamines/metabolism , Timolol/metabolism , Adult , Aged , Blood Pressure/drug effects , Chronic Disease , Humans , Intestinal Absorption , Kidney Diseases/physiopathology , Kinetics , Middle Aged , Pulse/drug effects , Renal Dialysis , Saliva/metabolism , Timolol/blood , Timolol/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...